natgillin/translations-raw huggingface dataset:
Use of the B cell of claim 12 to make a hybridoma comprising a rearranged immunoglobulin light chain gene sequence derived from the mouse of claim 1, the rearranged sequence comprising a hVλ gene segment, a hJλ gene segment and a mouse Ck gene at an endogenous mouse immunoglobulin k light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained, where the hybridoma expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence. 
Primjena B stanice prema zahtjevu 12 za izradu hibridoma koji se sastoji od preuređene sekvencije gena lakog imunoglobulinskog lanca dobivene iz miša prema zahtjevu 1, preuređene sekvencije koja se sastoji od hVλ segmenta gena, hJλ segmenta gena funkcionalno povezanog s mišjim Ck segmentom gena na mišjem lokusu endogenog lakog k imunoglobulinskog lanca, pri čemu se na spomenutom lokusu održava k element intronskog pojačivača uzlazno od Ck gena (označeno kao Eki) i 3'k pojačivač silazno od Ck gena (označeno kao Ek3'), i pri čemu hibridom izražava antitijelo koje se sastoji od lakog lanca koji sadrži preuređenu humanu Vλ-Jλ sekvenciju i mišju Ck sekvenciju.
receiving data from a random sequencing of a portion of the nucleic acid molecules contained in the biological sample obtained from a pregnant female subject, wherein the biological sample includes nucleic acid molecules, wherein the portion represents a fraction of the human genome; 
izvođenje sekvencijskog postupka nasumce na barem jednom dijelu od većeg broja molekula nukleinske kiseline, koje su u sadržaju biološkog uzorka, gdje taj dio na kojem je izveden sekvencijski postupak, predstavlja frakciju humanog genoma;
based on the dataset: 
te na temelju sekvencijskog postupka:
determining a first amount of chromosome 21 from sequences identified as originating from chromosome 21; 
određivanje prve količine prvog kromosoma iz sekvenci koje su identificirane da imaju podrijetlo iz prvog kromosoma;
The product of any preceding claim, wherein the nucleic acid molecules of the biological sample have been enriched for sequences less than 200 bp. 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka obogaćene za sekvence manje od 200 bp.
An iduronate-2-sulfatase (IDS) composition having an amino acid sequence of SEQ ID NO: 1, wherein a cysteine residue at position 59 in the IDS amino acid sequence is converted into formylglycine (FGly) at a molar ratio of 65% or higher, preferably at a molar ratio of 75% or higher. 
Pripravak iduronat-2-sulfataze (IDS) čija je aminokiselinska sekvenca SEQ ID broj: 1, gdje je cisteinski ostatak na položaju 59 u IDS aminokiselinskoj sekvenci pretvoren u formilglicin (FGly) u molarnom omjeru od 65% ili više, poželjno u molarnom omjeru od 75% ili više.
The IDS composition of claim 1, wherein the IDS having the amino acid sequence of SEQ ID NO: 1 contains mannose-6-phosphate in an amount of 2.0 to 4.0 moles per mole of IDS, preferably in an amount of 2.5 to 3.0 moles per mole of IDS. 
IDS pripravak prema zahtjevu 1, gdje IDS čija je aminokiselinska sekvenca SEQ ID broj: 1 sadrži manozu-6-fosfat u količini od 2.0 do 4.0 mola po molu IDS-a, poželjno u količini od 2.5 do 3.0 mola po molu IDS-a.
culturing a recombinant cell strain transformed with a gene encoding IDS represented by SEQ ID NO: 1 and obtaining the culture; and 
uzgoj kulture rekombinantnog staničnog soja transformiranog genom koji kodira IDS predstavljen kao SEQ ID broj: 1 i dobivanje kulture; i
purifying the culture through anion exchange chromatography, hydrophobic chromatography, cation exchange chromatography, and affinity chromatography, wherein the cation exchange chromatography is performed using an eluting buffer with a pH of 4.0 to 6.0. 
pročišćavanje kulture kroz anionsko izmjenjivačku kromatografiju, hidrofobnu kromatografiju, kationsko izmjenjivačku kromatografiju, i afinitetnu kromatografiju, gdje se kationsko izmjenjivačka kromatografija provodi pomoću eluacijskog pufera čiji je pH od 4.0 do 6.0.
culturing the recombinant cell strain in the presence of a hydrolysate in a serum-free medium and obtaining the culture; 
uzgoj kulture rekombinantnog staničnog soja u prisutnosti hidrolizata u mediju bez seruma te dobivanje kulture;
purifying IDS from the culture through anion exchange chromatography, hydrophobic chromatography, cation exchange chromatography and affinity chromatography; and EP 12803297.6 
pročišćavanje IDS-a iz kulture kroz anionsko izmjenjivačku kromatografiju, hidrofobnu kromatografiju, kationsko izmjenjivačku kromatografiju, i afinitetnu kromatografiju; i EP 12803297.6
A method for preparing a formulation, comprising formulating the composition according to claims 1 or 2 with a pharmaceutically acceptable carrier, and optionally with one or more substance(s) selected from the group consisting of a buffer, a carbohydrate, a stabilizer, an antioxidant, a bacteriostatics, a chelating agent, an adjuvant, a suspending agent, a thickener, and a preservative. 
Postupak pripreme oblika koji obuhvaća oblikovanje pripravaka prema zahtjevima 1 ili 2 s farmaceutski prikladnim nosačem, i po izboru s jednom ili više tvari izabranih iz skupine koju čine pufer, ugljikohidrat, stabilizator, antioksidans, bakteriostatik, sredstvo za keliranje, adjuvans, sredstvo za suspendiranje, zgušnjivač i konzervans.
A system according to claim 1 wherein the length (Lc) of the cavity is between 2 m and 10 m, the distance (Hc) of the top wall (19) from the interface plane (30) being between 0.2 m and 1.5 m and the width W being between 0.5 m and 1.5 m. 
Sustav sukladno zahtjevu 1 pri čemu je duljina (Lc) šupljine između 2 m i 10 m, udaljenost (Hc) gornjeg zida (19) od ravnine sučelja (30) je između 0.2 m i 1.5 m a širina W je između 0.5 m i 1.5 m.
A process for the preparation of the compound of formula IV, comprising the steps of: 
Postupak pripreme spoja formule IV, [image] koji obuhvaća korake:
mixing (6-fluoro-1H-indol-3-yl)acetonitrile, NH3 in water and a transition metal catalyst in an alcoholic solvent; and 
miješanje (6-fluoro-1H-indol-3-il)acetonitrila, NH3 u vodi i prijelaznog metalnog katalizatora u alkoholnom otapalu; i
hydrogenating the mixture with H2. 
hidrogeniranje smjese s H2.
The process of claim 1, wherein the transition metal catalyst is RaNi. 
Postupak prema zahtjevu 1, gdje je prijelazni metalni katalizator RaNi.
The process of claim 2 or 6, wherein the nominal composition of aluminium in the RaNi is 5% and the median particle size of the RaNi is 33 microns. 
Postupak prema zahtjevu 2 ili 6, gdje je nominalni sastav aluminija u RaNi 5% i medijan veličine čestica RaNi je 33 mikrona.
dissolving the compound of formula IV in an alcoholic solvent; 
otapanje spoja formule IV u alkoholnom otapalu;
The process according to claim 12, where the reducing agent is sodium borohydride. 
Postupak prema zahtjevu 12, gdje je reducens natrijev borohidrid.
The process according to claim 12 or 13, further comprising conversion of the compound of formula I to the HCl salt thereof by addition of HCl, optionally followed by purification of the resulting salt. 
Postupak prema zahtjevu 12 ili 13, dalje obuhvaća pretvorbu spoja formule I u njegovu HCl sol salt putem dodavanja HCl, nakon čega po izboru slijedi pročišćavanje dobivene soli.
A gypsum wall board having a core of an organic-inorganic composite comprising a mixture of: 
Zidna gips ploča, naznačena time, da ima jezgru od organsko-anorganskog kompozita koji sadrži sljedeću smjesu:
a cold water-insoluble substituted starch having a degree of substitution of between 1.5 and 2.5 wt%, said starch being substituted with at least one ether or ester group and having a weight percent solids at a viscosity of 1000 cps and a temperature of 65.6 °C (150 °F) in a range from 9 to 43%; water; and 
supstituirani škrob koji nije topiv u hladnoj vodi, koji ima stupanj supstitucije između 1,5 i 2,5 masenih %, gdje je navedeni škrob supstituiran s najmanje jednom eterskom skupinom ili esterskom skupinom te ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 9 do 43%;
an inorganic phase comprising gypsum, the inorganic phase being at least partially hydrated by the water, wherein the substituted starch is present as a film substantially dispersed throughout the organic-inorganic composite such that the organic-inorganic composite is substantially strengthened. 
voda; i anorganska faza koja sadrži gips, pri čemu je anorganska faza barem djelomično hidratizirana vodom, dok je supstituirani škrob prisutan kao film u biti raspršen kroz cijeli organsko-anorganski kompozit tako da se time organsko-anorganski kompozit bitno ojačava.
The gypsum wall board according to claim 1, wherein the substituted starch is hydroxyethylated, hydroxypropylated, or acetylated. 
Zidna gips ploča prema zahtjevu 1, naznačena time, da supstituirani škrob je hidroksietiliran, hidroksipropiliran ili acetiliran.
The gypsum wall board of claim 2, wherein the at least one ether group is a hydroxypropyl group and the weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 14 percent to 20 percent. 
Zidna gips ploča prema zahtjevu 2, naznačena time, da najmanje jedna eterska skupina je hidroksipropilna skupina i da ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 14 do 20%.
The gypsum wall board of claim 2, wherein the at least one ether group is a hydroxyethyl group and the weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 17 percent to 30 percent. 
Zidna gips ploča prema zahtjevu 2, naznačena time, da najmanje jedna eterska skupina je hidroksietilna skupina i da ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 17 do 30%.
The gypsum wall board of claim 4, wherein the weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 17 percent to 21 percent. 
Zidna gips ploča prema zahtjevu 4, naznačena time, da je maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 17 do 21%.
The gypsum wall board of claim 6, wherein the substituted starch is substantially amylopectin. 
Zidna gips ploča prema zahtjevu 6, naznačena time, da je supstituirani škrob u biti amilopektin.
The gypsum wall board of claim 1, wherein the substituted starch is of an acid-thinned starch and the at least one ether group is of a hydroxypropyl group. 
Zidna gips ploča prema zahtjevu 1, naznačena time, da je supstituirani škrob od škroba razrjeđenog kiselinom i barem jedna eterska skupina je iz hidroksipropilne skupine.
The gypsum wall board of claim 9, wherein the degree of substitution is selected in a range from 1.5 to 2.5 weight percent hydroxypropyl. 
Zidna gips ploča prema zahtjevu 9, naznačena time, da je stupanj supstitucije odabran iz raspona od 1,5 do 2,5 masenih postotaka hidroksipropila.
The gypsum wall board of claim 13, wherein the fibers are glass fibers. 
Zidna gips ploča prema zahtjevu 13, naznačena time, da vlakna su staklena vlakna.
The gypsum wall board of claim 15, wherein the cellulose ether is of hydroxypropylmethyl cellulose. 
Zidna gips ploča prema zahtjevu 15, naznačena time, da celulozni eter je hidroksipropilmetil-celuloza.
selecting a cold water-insoluble substituted starch having a degree of substitution of between 1.5 and 2.5 wt%, a degree of polymerization, at least one ether or ester substituent group and a weight percent solids at a viscosity of 1000 cps and a temperature of 65.6 °C (150 °F) in a range from 9 to 43%, such that the substituted starch is insoluble in water in the mixing temperature range; 
odabir supstituiranog škroba koji nije topiv u hladnoj vodi, koji ima stupanj supstitucije između 1,5 i 2,5 masenih %, stupanj polimerizacije, najmanje jednu etersku ili estersku supstituentsku skupinu te ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 9 do 43%, tako da supstituirani škrob nije topiv u vodi u opsegu miješanja temperatura;
mixing the substituted starch, an inorganic phase comprising gypsum and water in a continuous process at a temperature within the mixing temperature range; forming the gypsum wall board; 
miješanje supstituiranog škroba, anorganske faze koja sadrži gips i vodu, u kontinuiranom procesu na temperaturi unutar opsega miješanja temperatura; oblikovanje zidne gips ploče;
raising the temperature above the mixing temperature range, wherein the substituted starch at least partially dissolves in the water; and setting and drying the gypsum wall board such that the substituted starch forms a continuous polymeric film within the core. 
podizanje temperature iznad opsega miješanja temperatura, pri čemu se supstituirani škrob barem djelomično rastapa u vodi; i polaganje i sušenje zidne gips ploče tako da supstituirani škrob stvara kontinuirani polimerni film unutar jezgre.
a cavity (4) for holding the liquid, the cavity being bounded by walls at the sides (3) and at the bottom (2), 
šupljinu (4) za držanje tekućine, te je šupljina omeđena sa stjenkama na stranicama (3) i na dnu (2),
a closure (40 & 43) for closing off the cavity, the closure having a piercing region for inserting a cannula into the cavity, 
zatvarač (40 i 43) za zatvaranje šupljine, te zatvarač ima područje za probijanje za umetanje kanile u šupljinu,
a bottom casing (20) which surrounds the walls of the cavity at its base, 
dno kućišta (20) koje okružuje stjenke šupljine u njezinom podnožju,
the top casing surrounds the pierceable closure with the exception of the piercing region. 
vrh kućišta okružuje zatvarač koji je moguće probiti s izuzetkom područja za probijanje.
Container according to claim 1, characterised in that the walls that bound the cavity are made of glass. 
Spremnik prema zahtjevu 1, naznačen time da su stjenke koje povezuju šupljinu izrađene od stakla.
Container according to claim 6, characterised in that the closure has an apron that is secured to the flange of the primary vessel. 
Spremnik prema zahtjevu 6, naznačen time da zatvarač ima zaštitni dio koji je pričvršćen na prirubnicu primarne posude.
Container according to any of claims 1 to 7, characterised in that the top casing has an upper region that is of tapered cross-section and a lower region of widened cross-section in the manner of a telescopic cylinder, the upper region being provided for connection to the closure and the lower region fitting flush with the walls that enclose the cavity. 
Spremnik prema bilo kojem od zahtjeva 1 do 7, naznačen time da vrh kućišta ima gornje područje koje ima poprečni presjek koji se sužava i donje područje s poprečnim presjekom koji se širi na način kao za teleskopski cilindar, te je gornje područje predviđeno za spajanje sa zatvaračem i donje područje je postavljeno u ravnini sa stjenkama koje omeđuju šupljinu.
Use according to claim 10, characterised in that the container contains a single dose of the radioactive substance. 
Uporaba prema zahtjevu 10, naznačena time da spremnik sadrži jednu dozu radioaktivne tvari.
closing the filled primary vessel, 
zatvaranje napunjene primarne posude,
providing the primary vessel with a bottom casing at its base, 
osiguravanje primarne posude s dnom kućišta u njenom podnožju,
Method according to claim 12, characterised in that the liquid is a single dose of a medicament, particularly a radiotherapeutic agent. 
Postupak prema zahtjevu 12, naznačen time da je tekućina jedna doza lijeka, naročito sredstvo za radioterapiju.
The compound or salt for use according to claim 1, wherein R2 is H. 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu R2 je H.
The compound or salt for use according to claim 2, wherein n is 0. 
Spoj ili sol za upotrebu prema zahtjevu 2, pri čemu n je 0.
The compound or salt for use according to claim 3, wherein p is 1. 
Spoj ili sol za upotrebu prema zahtjevu 3, pri čemu p je 1.
The compound or salt for use according to claim 4, wherein R5b is H. 
Spoj ili sol za upotrebu prema zahtjevu 4, pri čemu R5b je H.
The compound or salt for use according to claim 5, wherein a is 0. 
Spoj ili sol za upotrebu prema zahtjevu 5, pri čemu a je 0.
The compound or salt for use according to claim 6, wherein b is 0. 
Spoj ili sol za upotrebu prema zahtjevu 6, pri čemu b je 0.
The compound or salt for use according to claim 6, wherein b is 1. 
Spojevi ili sol za upotrebu prema zahtjevu 6, pri čemu b je 1.
A compound or salt for use according to claim 1, wherein the compound has formula: wherein: 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu Spoj ima formulu:
A compound or salt for use according to claim 1, wherein the compound is selected from: 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu je spoj izabran od: N-benzil-4-(benzilamino)-N’-hidroksi-1,2,5-oksadiazol-3-karboksimidamid;
The compound or salt for use according to claim 1, wherein said cancer is selected from cancer of the colon, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma. 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu je spomenuti rak izabran od raka debe1og crijeva, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, cervikalnog raka, raka testisa, raka bubrega, raka glave i vrata, limfoma, leukemije i me1anoma.
is selected from the group consisting of 
je izabran iz grupe koja se sastoji od
X2-X3 is selected from the group consisting of 
N→O; -X3 je izabran iz grupe koja se sastoji od
X4, X5, X6 and X7 are each selected from the group consisting of N, 
, X5, X6 i X7 su svaki izabran iz grupe koja se sastoji od N,
is selected from the group consisting of hydrogen, halogen, 
je izabran iz grupe koja se sastoji od vodika, halogena,
is optionally present at one or more of the ring carbon atoms, and is independently selected from the group consisting of halogen, -O-C1-6 alkyl, 
je izborno prisutan na jednom ili više atoma ugljika u prstenu, i nezavisno je izabran iz grupe koja se sastoji od halogena, -O-C1-6 alkil,
is optionally present at one or more of the ring atoms, and is selected from the group consisting of 
je izborno prisutan na jednom ili više atoma u prstenu, i izabran je iz grupe koja se sastoji od
-O-heterocyclyl, -NRARB, wherein RA and RB are selected from the group consisting of 
-O-heterociklil, -NRARB, gdje su RA i RB izabrani iz grupe koja se sastoji od
A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 is present at one of the ring atoms, and is selected from the group consisting of 
Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, gdje R4 je prisutan na jednom od atoma prstena, i izabran je iz grupe koja se sastoji od
A compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein R4 is selected from the group consisting of 
Spoj prema patentnom zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, pri čemu R4 je izabran iz grupe koja se sastoji od
-S-C1-6 alkyl, wherein said alkyl or heteroaryl R4 moiety is optionally substituted with one or more halogen, hydroxy, 
-S-C1-6 alkil, pri čemu je navedena alkil ili heteroaril R4 grupa izborno supstituirana sa jednim ili više halogena, hidroksi,
-C1-6 alkyl, optionally substituted with halogen, or 
-C1-6 alkil, izborno supstituiran sa halogenom, ili
A compound of claim 1, which is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, koje je izabran iz grupe koja se sastoji od:
A compound of any of claims 1-20 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder mediated by the muscarinic M1 receptor, wherein said disease or disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders. 
Spoj prema bilo kojem od patentnih zahtjeva 1-20 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju bolesti ili poremećaja posredovane/posredovanog preko muskarinskog M1 receptora, pri čemu je navedena bolest ili poremećaj izabrana/izabran iz grupe koja se sastoji od Alzheimerove bolesti, šizofrenije ili poremećaja spavanja.
A pharmaceutical composition comprising as an active ingredient a compound of claim 5 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži kao aktivni sastojak spoj prema zahtjevu 5 i farmaceutski prihvatljiv nosač.
A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 5 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za oralnu primjenu naznačen time da sadrži kao aktivni sastojak spoj prema zahtjevu 5 i farmaceutski prihvatljiv nosač.
The composition for use according to claim 13 wherein said PI3K related disease or disorder is a cell proliferative disorder, preferably wherein the cell proliferative disorder is a cancer, such as papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease. 
Pripravak za uporabu prema zahtjevu 13 naznačen time da navedena bolest ili poremećaj povezan s PI3K je poremećaj proliferacije stanice, poželjno gdje je poremećaj proliferacije stanice rak, kao što je papilom, blastogliom, Kapozijev sarkom, melanom, karcinom ne-malih stanica pluća, rak jajnika, rak prostate, karcinom skvamoznih stanica, astrocitom, rak glave, rak vrata, rak mokraćnog mjehura, rak dojke, rak pluća, kolorektalni rak, rak tiroidne žlijezde, rak gušterače, rak želuca, hepatocelularni karcinom, leukemija, limfom, Hodgkinova bolest i Burkittova bolest.
or Ra and Rb together with the carbon atom they are attached form a C3-6cycloalkyl group; 
ili Ra i Rb, zajedno s atomom ugljika na kojeg su vezani, tvore C3-6cikloalkilnu skupinu;
The single-handle dual-control thermostatic faucet according to any preceding claim, wherein a hot water feed pipe (41) and a cold water feed pipe (42) are included, both of which are respectively connected to the hot water and cold water inlets (81, 82) of the valve body. 
Termostatska slavina s jednom ručkom i dvojnom kontrolom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su uključene cijev za dovod vruće vode (41) i cijev za dovod hladne vode (42), od kojih su obje odgovarajuće povezane s ulazom vruće vode i ulazom hladne vode (81, 82) na tijelu ventila.
R4/R4' are independently from each other hydrogen, C1-4-alkyl, CH2- C1-4-alkoxy or may form together with the carbon atom to which they are attached, a C3-C6-cycloalkyl; 
/R4' su međusobno neovisno vodik, C1-4-alkil, CH2-C1-4-alkoksi ili zajedno s atomom ugljika na kojega su priključeni, mogu tvoriti -6-cikloalkil;
and R2 may form together with the carbon atom to which they are attached a C3-6-cycloalkyl; or if n is 0 and Y is -N(R6)-, then R6 and R2 may form together with the carbon atom and the nitrogen atom to which they are attached a C3-6-cycloalkyl; 
i R2 zajedno s atomom ugljika na kojega su priključeni, mogu tvoriti C3-6-cikloalkil; ̧ ili ako n je 0, a Y je -N(R6)-, tada R6 i R2 zajedno s atomom ugljika i atomom dušika na koje su priključeni,mogu tvoriti C3-6-cikloalkil;
or if n and m are 0, then R2 and R7 may form together with the carbon atoms to which they are attached a C3-6-cycloalkyl; 
ili ako su n i m jednaki 0, tada R2 i R7 zajedno s atomima ugljika na koje su priključeni, mogu tvoriti C3-6-cikloalkil;